Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on Sterile Injectables Outsourcing

Growth Opportunities Fuel the Growth Pipeline Engine™

Key Takeaways

Scope of Analysis

Forecast Framework—CDMO

Forecast Methodology—Sterile Injectable Outsourcing

Forecast Assumptions

Key Growth Metrics

Growth Drivers

Growth Restraints

Revenue Forecast

Revenue Forecast by Product Type

Revenue Forecast Analysis

Therapeutic Area Overview

Therapeutic Area Overview (continued)

Supply Chain and the Evolving Role of Vendors

Recent Trends Driving Collaborations & Expansions

Recent Trends Driving Collaborations & Expansions (continued)

Capability Overview of Select CDMOs

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe

CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—APAC

Smartification of Injectable Delivery Device

Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities

Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities (continued)

Growth Opportunity 2: Strategic Partnerships that Provide Integrated Injectable Drug Product and Device Service

Growth Opportunity 2: Strategic Partnerships to Provide Integrated Injectable Drug Product and Device Service (continued)

Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics

Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics (continued)

List of Exhibits

Legal Disclaimer